Question to the Department for Business and Trade:

To ask the Secretary of State for Business and Trade, what the mitigations are under the US Most Favoured Nation drug pricing initiative as referred to in the UK-US Economic Prosperity Deal.

The US has committed to ensuring that access to medicines and launches of new innovative medicines in the UK are not inadvertently impacted by the US’s ‘Most Favoured Nation’ policy, thereby reducing the risk to the UK where the NHS has managed to secure lower prices for medicines.

Further work to finalise underpinning details is ongoing.